Last updated
Survodutide and retatrutide share the receptor that sets them apart from semaglutide and tirzepatide — glucagon. Survodutide pairs glucagon with GLP-1 (a dual agonist); retatrutide adds GIP on top of both (a triple). Both are investigational, and the interesting question is what that third receptor actually buys — and where each one’s evidence is strongest.
Research reference only. Not medical advice, prescribing guidance, or a product recommendation.
| Dimension | Survodutide | Retatrutide |
|---|---|---|
| Receptor targets | Glucagon-R + GLP-1R | GIP-R + GLP-1R + glucagon-R |
| Agonism class | Dual agonist (glucagon/GLP-1) | Triple agonist |
| Developer | Boehringer Ingelheim / Zealand (BI 456906) | Eli Lilly (LY3437943) |
| Distinctive program | MASH — FDA Breakthrough Therapy | Obesity — largest Phase 2 weight figure |
| Peak weight ↓ (trial) | Double-digit mean (Phase 2/3, dose-dependent) | ~24% (Phase 2, 48 wk, 12 mg) |
| Shared glucagon rationale | Energy expenditure + hepatic-fat mobilization | Energy expenditure + hepatic-fat mobilization |
| Extra receptor | — (no GIP) | GIP — complementary insulinotropic/adipose signal |
| Approval status | Investigational (Phase 3 SYNCHRONIZE) | Investigational (Phase 3 TRIUMPH) |
| Molecular weight | 4232 Da | 4731.5 Da |
Both molecules recruit glucagon for the same reasons: on top of GLP-1’s appetite and glycemic effects, glucagon-receptor activation is studied for raising energy expenditure and mobilizing fat from the liver. That shared logic is why survodutide’s standout data is in the liver — in a Phase 2 MASH trial (NEJM 2024), 62% of patients on the 4.8 mg dose achieved MASH improvement without worsening fibrosis versus 14% on placebo, with fibrosis improvement up to ~52% — earning it FDA Breakthrough Therapy designation for MASH.
Retatrutide keeps the glucagon and GLP-1 arms and adds a third receptor, GIP, which contributes a complementary insulinotropic and adipose signal. Its headline is weight: ~24% mean reduction at the highest Phase 2 dose, the largest reported for the incretin class. So the practical contrast is emphasis — survodutide is the glucagon/GLP-1 dual with the strongest liver-disease evidence, retatrutide the triple with the largest weight figure. Whether the added GIP is worth the extra complexity is exactly what the two Phase 3 programs are meant to answer.
62% vs 14% (placebo)
MASH improvement, no worsening fibrosis · n=293 · 48 wk — NEJM 2024; fibrosis improvement up to ~52% vs ~26%
~24% vs ~2% (placebo)
Mean body-weight change · n=338 · 48 wk — Jastreboff et al., NEJM 2023; highest-dose arm
Reporting — neither FDA-approved
Confirmatory obesity/metabolic · Ongoing — No head-to-head between them has been run
These are close cousins that emphasize different endpoints. Survodutide, the glucagon/GLP-1 dual, has the strongest liver-disease signal — its MASH data is what earned Breakthrough designation. Retatrutide, the triple, adds GIP and reports the largest weight reduction in the class. Both are investigational, both rely on the glucagon arm for energy expenditure and liver fat, and there is no head-to-head trial between them — so the comparison is one of mechanism and program focus, not a settled ranking. These are population means, not individual predictions.
Survodutide is a glucagon/GLP-1 dual agonist; retatrutide adds a third receptor, GIP, making it a GIP/GLP-1/glucagon triple agonist. Both use the glucagon arm for energy expenditure and liver-fat reduction. Survodutide’s strongest data is in MASH (fatty liver disease); retatrutide’s is the largest weight loss reported for the class.
Survodutide has the more advanced dedicated liver program — in a Phase 2 MASH trial (NEJM 2024) 62% on the 4.8 mg dose achieved MASH improvement without worsening fibrosis versus 14% on placebo, and it holds FDA Breakthrough Therapy designation for MASH. Retatrutide is also studied for hepatic fat but is framed primarily around weight.
Retatrutide reported ~24% mean weight loss at the highest Phase 2 dose, the largest for the incretin class. Survodutide has reported double-digit mean reductions. These come from separate trials, not a head-to-head, and both are still in Phase 3.
No. Both are investigational — survodutide (Boehringer Ingelheim / Zealand) in the SYNCHRONIZE program and retatrutide (Eli Lilly) in TRIUMPH. Neither is FDA-approved. This page is a research and educational reference.
Mechanism, evidence, and trade-offs between Survodutide and Retatrutide — citation-backed answers grounded in PubMed, PubChem, and ClinicalTrials.gov.